THERAPEUTICS

Review: clonidine is more effective than placebo for long term smoking cessation, but has side effects


Clinical impact ratings GP/FP/Primary care ★★★★★★★ IM/Ambulatory care ★★★★★★★

Q Is oral or transdermal clonidine more effective than placebo for achieving long term smoking cessation?

METHODS

Data sources: Cochrane Tobacco Addiction Group trials register, Medline, and PsyCLIT (up to May 2004); and the email newsgroup of the Society for Research on Nicotine and Tobacco for unpublished studies.

Study selection and assessment: randomised, placebo controlled trials that compared oral or transdermal clonidine (maximum daily dosage ≥0.2 mg) with placebo. Methodological quality of individual studies was assessed for randomisation procedure and blinding.

Outcomes: smoking cessation at ≥12 weeks (biochemical verification of sustained abstinence assessed ≥12 wk after the end of treatment).

MAIN RESULTS

6 trials (n = 776) met the inclusion criteria. Assessment of blinding and details of the randomisation procedure were not reported in any of the studies. 4 of the 6 trials used biochemical verification of smoking abstinence using plasma cotinine (<15 μg/ml), salivary cotinine (<20 μg/ml), expired carbon monoxide (<10 ppm), or random plasma thiocyanate monitoring. Volunteer participants were recruited from community settings (5 trials) and an internal medicine clinic, and were described as smokers (>10 cigarettes/d, 2 trials) or heavy smokers (>20 cigarettes/d or >1 pack/d for 3 years, 4 trials). Clonidine was taken orally (dosage varied from a maximum of 0.15–0.45 mg/d (3 trials) or transdermally (dosage 0.1–0.3 mg/d (3 trials). Dosage was individualised according to tolerance or body weight, and built up before quit day. Participants in 5 trials received (3 trials). Dosage was individualised according to tolerance or body weight, and built up before quit day. Participants in 5 trials received

CONCLUSION

Oral or transdermal clonidine is more effective than placebo for achieving long term smoking cessation but is associated with side effects including dry mouth and sedation.

For correspondence: Dr S Gourlay, Genentech Inc, South San Francisco, CA, USA. gao@gene.com
Sources of funding: National Heart Foundation Australia; US Public Health Service; NHS Research and Development National Cancer Programme.

Clonidine v placebo for smoking cessation at ≥12 months*

<table>
<thead>
<tr>
<th>Number of trials</th>
<th>Number of patients</th>
<th>Weighted event rates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Clonidine</td>
</tr>
<tr>
<td>6</td>
<td>776</td>
<td>23%</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary; weighted event rates, RBI, NNT, and CI calculated from data in article using a fixed effects model.

Abstract and commentary also appear in ACP J Club.

Commentary

Although clonidine has been used to treat the symptoms of withdrawal for several decades,1 its use for smoking cessation has only recently been recommended. The systematic review by Gourlay et al supports the conclusions of a US Public Health Service clinical guideline on treating tobacco use and dependence.2 Clinicians should now have confidence that clonidine, along with nicotine replacement therapy (NRT) (gum, patch, inhaler, intranasal spray, or tablets) and antidepressant therapy (bupropion or nortriptyline), is an effective option for helping tobacco users quit.

Clonidine is best for patients who have agitation or anxiety that is unrelied by NRT or antidepressants, and should be specifically considered when treating patients with withdrawal symptoms who use multiple drugs (eg, opiates, benzodiazepines, or alcohol).

Clonidine is considered a “second line” medication for several reasons. Special care should be taken when prescribing clonidine to older patients because of such well known side effects as drowsiness, dry mouth, and postural hypotension. The dose should be tapered at the end of therapy to avoid the withdrawal effects of clonidine itself. Although the level of evidence for effectiveness is high, only data from 1 of the 6 small studies that were pooled showed a statistically significant difference. The US Food and Drug Administration considers the use of clonidine for tobacco cessation to be an “off label” indication.

While it is not clear which dose or route of administration is the most effective, oral dosing has the added attraction of being relatively inexpensive (<$0.50/d) compared with NRT or bupropion, which can cost >$3.00/day.

All the studies in the review by Gourlay et al included substantial amounts of behavioural support, which underscores the imperative that clinicians should always focus on behaviour change issues when addressing tobacco dependence.

Helping patients quit smoking is one of the most important things that healthcare providers can do. While clonidine may not be for everyone, it might be useful for patients who have extreme withdrawal symptons or for those who do not improve with nicotine replacement or antidepressant therapy.

Charles J Bentz, MD
Portland, Oregon, USA